Risk of Subsequent Primary Cancer in Thyroid Cancer Survivors: A Nationwide Population-Based Study
暂无分享,去创建一个
[1] K. Jung,et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019 , 2022, Cancer research and treatment.
[2] Mijin Kim,et al. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study. , 2022, European journal of endocrinology.
[3] Hun‐Sung Kim,et al. Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research , 2021, Journal of lipid and atherosclerosis.
[4] P. Piaggi,et al. Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? , 2020, International journal of cancer.
[5] S. Park,et al. Incidence of Hypoparathyroidism After Thyroid Cancer Surgery in South Korea, 2007-2016. , 2019, JAMA.
[6] S. Ezzat,et al. A primer on the genetics of medullary thyroid cancer. , 2019, Current oncology.
[7] M. Tucker,et al. Risk of Second Primary Bone and Soft-Tissue Sarcomas Among Young Adulthood Cancer Survivors. , 2019, JNCI cancer spectrum.
[8] C. Goldsmith,et al. A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.
[9] Ken R. Smith,et al. Aging-Related Disease Risks among Young Thyroid Cancer Survivors , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[10] E. Limbert,et al. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? , 2017, Thyroid : official journal of the American Thyroid Association.
[11] L. Morris,et al. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. , 2015, Thyroid : official journal of the American Thyroid Association.
[12] Douglas B. Evans,et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.
[13] J. Chung,et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: A nationwide, population‐based study in Korea , 2015, Cancer.
[14] Shuangge Ma,et al. The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. , 2013, Thyroid : official journal of the American Thyroid Association.
[15] J. Tward,et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[16] E. Ron,et al. Thyroid cancer and multiple primary tumors in the SEER cancer registries 1 , 2005, International journal of cancer.
[17] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[18] P. Hall,et al. Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.
[19] K. Hemminki,et al. Multiple primary cancers as clues to environmental and heritable causes of cancer and mechanisms of carcinogenesis. , 2004, IARC scientific publications.